ema semaglutide Novo Nordisk secures approval for Rybelsus label update Europe allows Novo to include

Bone health during weight loss

Fast Visit A focused option when you want a simple wellness injection rather than a longer IV therapy visit

Many people continue treatment for one to two years or longer to achieve and maintain their health goals

Advanced GLP-1 Weight Loss Advanced GLP-1s combine dual-agonist action to improve weight loss outcomes by enhancing insulin sensitivity and reducing hunger, integrated into a customized care plan

Topline results from the ESSENCE trial demonstrated that 62.7% of patients who received once-weekly Wegovy 2.4 mg SC had improved steatohepatitis and 37% had improved liver fibrosis compared 34.1% and 22.5%, respectively, of patients who received placebo